Griggio et al. nicely showed that the combination of an HIF-1α inhibitor with ibrutinib, a BTK inhibitor, showed a synergistic cytotoxic effect in TP53-disrupted CLL cells [27]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.